---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000043"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:14:27.742997+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nurix appoints former Merck CMO Roy Baynes to board of directors

## Summary
- Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.
- Received initial option for 50,000 shares vesting over 3 years; annual cash retainers of $50,000 (board) and $5,000 (committee).
- Served on Medical Advisory Board since 2023; will advise on clinical development including NX-5948 for CLL.
- No family relationships or material interests with directors/officers; standard indemnification agreement executed.

## SEC filing metadata
- accession: 0001549595-25-000043
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000043/0001549595-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000043/nrix-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000043
- JSON: https://secwatch.observer/filing/0001549595-25-000043.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.